Huiyuan Biotechnology

HD Biosciences (Huiyuan Biotechnology) is a leading biology-focused contract research organization (CRO) headquartered in Shanghai, China. The company provides a comprehensive suite of services including plate-based pharmacology, hit-to-lead optimization, ADME/PK, and in vivo pharmacology to global pharmaceutical and biotech clients. Founded in 2002, it established a strong reputation for its expertise in GPCRs, ion channels, and kinases. In 2017, HD Biosciences was acquired by WuXi AppTec, significantly expanding WuXi's discovery biology capabilities and integrated R&D services. Today, it operates as a key subsidiary within the WuXi AppTec ecosystem, supporting drug discovery programs from early target validation through preclinical development.